^
Contact us to learn more about
our Premium Content: News alerts, weekly reports and conference plannersTEST:Theralink Assay
Contact us to learn more about our Premium Content:
News alerts, weekly reports and conference planners
Company:
TheralinkType:
Laboratory Developed Test
The Theralink assay uses Reverse Phase Protein Array (RPPA) technology to measure the abundance and activation of cell surface receptor proteins and their downstream signaling pathways. Theralink measures phosphorylated proteins in tumor tissues. Phosphorylated proteins represent active targets for drugs. Examples of tumor indications for application development include, but are not limited to: Breast Cancer, Pancreatic Cancer, Colorectal Cancer, Non-Small Cell Lung Cancer
Cancer:
Breast Cancer, Colorectal Cancer, Non Small Cell Lung Cancer, Pancreatic Cancer
Gene:
AKT1 (V-akt murine thymoma viral oncogene homolog 1), ALK (Anaplastic lymphoma kinase), ATM (ATM serine/threonine kinase), EGFR (Epidermal growth factor receptor), HER-2 (Human epidermal growth factor receptor 2), PDGFRA (Platelet Derived Growth Factor Receptor Alpha)
See More ...
AKT1 (V-akt murine thymoma viral oncogene homolog 1), ALK (Anaplastic lymphoma kinase), ATM (ATM serine/threonine kinase), EGFR (Epidermal growth factor receptor), HER-2 (Human epidermal growth factor receptor 2), PDGFRA (Platelet Derived Growth Factor Receptor Alpha), RET (Ret Proto-Oncogene), ROS1 (Proto-Oncogene Tyrosine-Protein Kinase ROS)
Method:
Reverse Phase Protein Array (RPPA) Technology
